Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY2787106 · 1 trial · 1 indication
Number of participants with one or more treatment emergent adverse event (TEAE) or any Serious AE (SAE). A summary of SAEs and other non-serious AEs, regardless of causality, is located in the Reported Adverse Event module.
This analysis assesses the mean change in Hemoglobin from baseline to the end of Cycle 4. The analysis was carried separately for Cohort B1 without supplemental iron and Cohort B2 with supplemental iron.
| Arm | Type | Description |
|---|---|---|
| LY2787106 Dose Escalation | EXPERIMENTAL | Part A: Dose escalation starting at 0.3 milligram/kilogram (mg/kg), intravenously (IV), day one of up to three 21-day cycles. |
| 10 mg/kg LY2787106 | EXPERIMENTAL | Part B: 10 mg/kg of LY2787106, administered IV, on day one of up to eight 7-day cycles. Participants who do not experience a stopping rule and who are felt to be benefiting during the defined treatment period may receive additional doses at the discretion of the investigator. |
| 10 mg/kg LY2787106+Iron | EXPERIMENTAL | Part B: 10 mg/kg of LY2787106, administered IV, on day one of up to eight 7-day cycles with daily oral iron supplementation. Participants who do not experience a stopping rule and who are felt to be benefiting during the defined treatment period may receive additional doses at the discretion of the investigator. |
| Name | Type | Description |
|---|---|---|
| LY2787106 | DRUG | Administered IV. |
| Iron Supplementation | DIETARY_SUPPLEMENT | Administered orally. |
Inclusion Criteria: * Have histological or cytological evidence of non-myeloid cancer (solid tumors, lymphomas or multiple myeloma) that is metastatic and/or incurable * Have been treated with at least one systemic (oral, intravenous, or subcutaneous) anti-cancer therapy or regimen * Have a hemoglo...
LY2787106 is an investigational small molecule being developed for the treatment of anemia. It is being studied in the context of cancer and anemia, with a Phase 1 clinical trial conducted in the United States. The drug is not yet approved and remains in clinical development.
LY2787106 is a small molecule, but its specific molecular target has not been disclosed in available information. The drug is being investigated for its potential role in treating anemia, particularly in patients with cancer, though the exact mechanism of action is not publicly detailed.
LY2787106 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The company is conducting clinical research on this investigational drug for the treatment of anemia.
LY2787106 is in Phase 1 clinical development. A Phase 1 study has been completed, and the drug is still investigational. It has not received FDA approval and is not yet available as a marketed therapy for anemia.
LY2787106 has been studied in one clinical trial, identified as NCT01340976, titled 'A Phase 1 Study of LY2787106 in Cancer and Anemia.' This trial was completed in the United States and enrolled 33 participants aged 18 years and older. The study was controlled but not randomized or double-blinded.
LY2787106 is not known to be the same as any other drug, as no alternative names have been reported. It is a distinct investigational compound developed by Eli Lilly and Company for the potential treatment of anemia.